Search

Displaying results 591 - 600 of 4591 in total
  1. Drug

    Levofloxacin

    go.drugbank.com/drugs/DB01137
    ApprovedInvestigational

    [A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663]

  2. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. … [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]

  3. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794] … [A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine.

  4. Indication

    Obesity

    go.drugbank.com/conditions/DBCOND0015947
    Drugs: Amphetamine · Benzphetamine · Bupropion · Fluoxetine · Lecithin, soybean · Lorcaserin +6 more
    Synonyms: Overweight and obesity
  5. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation.

  6. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme

  7. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential … This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069].

  8. Drug

    Idursulfase

    go.drugbank.com/drugs/DB01271
    ApprovedInvestigational

    Idursulfase is produced by recombinant DNA technology in a human cell line. … The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures.

  9. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    The immediate release tablet of Zileuton has been withdrawn from the US market.

  10. Drug

    Eslicarbazepine acetate

    go.drugbank.com/drugs/DB09119
    ApprovedInvestigational

    Eslicarbazepine's mechanism of action is not well understood, but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and stabilizing the inactivated state of